Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche AIDS drug development

Executive Summary

Hoffmann-La Roche seeking to out-license one of three AIDS drugs under development, the TAT-inhibitor RO 24-7429. In-progress Phase I trials, which were halted in April following the decision to license the drug, will continue under Roche until a partner is found, the company said. Roche will focus research efforts on its two other AIDS drugs, ddC (Hivid) ("The Pink Sheet" March 18, T&G- 6), for which the company is filing an NDA, and a protease inhibitor.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS019274

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel